B3-vitamin, Niacin, forskningsreferencer

Januar 1999

1. Alhadeff L, Gualtieri GT, Lipton M. Toxic effects of water-soluble vitamins. Nutr Rev 42: 33-40, 1984.
2. Bendich A, Cohen M. Nutrition and immunology. New York: Alan R. Liss. p 114-115, 1988.
3. Carlson LA, Hamsten A, and Asplund A. Pronounced Lowering of Serum Levels of Lipoprotein Lp(a) in Hyperlipidaemic Subjects Treated with Nicotinic Acid, J Intern Med 226, 271-6, 1989.
4. Cheraskin E, Ringsdorf WM Jr, Medford FH. The ‘ideal’ daily niacin intake. Int J Vit Nutr Res 46: 58-60, 1976.
5. Cleary JP. Vitamin B3 in the Treatment of Diabetes Mellitus: Case Reports and Review of the Literature. J Nutr Med 1: 217-25, 1990.
6. DiPalma JR and Thayer WS, Use of Niacin as a Drug, Ann Rev Nutr 11; 169-87, 1991.
7. Einstein N, Baker A, Galper J et al. Jaundice due to nicotinic acid therapy. Am J Digest Dis 20: 282-286, 1975.
8. El-Enein AMA et al., The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents, Nutr Rep Intl 28, 899-911, 1983.
9. Figge HL, Figge J, Souney PF et al. Nicotinic acid. A review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 8: 287-294, 1988.
10. Gaby SK. Vitamin intake and health: A scientific review. New York: Marcel Dekker. p 189-192, 1991.
11. Goldsmith GA, Miller ON, Unglaub WG. Efficiency of tryptophan as a niacin precursor in man. J Nutr 73: 172-176, 1961.
12. Grundy SM. Drug therapy in dyslipidemia. Scand J Clin Lab Invest 50: 63-72, 1990.
13. Illingworth DR et al., Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia, Arch Intern Med 154, 1586-95, 1994.
14. Jacob, RA, Swendseid, ME. Niacin. In: Present knowledge in nutrition. 7th edn. Washington DC: International Life Sciences Press. p 184-190, 1996.
15. Jonas WB et al. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res 45: 330-4, 1996.
16. Lefavi R. Lipid-lowering effects of a dietary nicotinic acid-chromium III complex in male athletes. FASEB J 5;6:A1645, 1991.
17. Lefavi R et al. Lipid-lowering effect of a dietary chromium III-nicotinic acid complex in male athletes. Nutr Res 13:239-49, 1993.
18. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high density lipoprotein cholesterol ratio. Arch Intern Med 148: 2493-5, 1988.
19. Mandrup Paulsen T. Nicitinamide in the Prevention of Insulin Dependent Diabetes Mellitus. Diabetes Metabol Rev 9: 295-309, 1993.
20. McKenney JM et al., A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients, JAMA 271, 672-7, 1994.
21. O’Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (I lexopal) in intermittent claudication of a controlled trial. Br J Clin Practice 42: 377-383, 1988.
22. Patterson JI, Brown RR, Lindswiler H et al. Exertion of tryptophan-niacin metabolites by young men. Effects of tryptophan, leucine, and vitamin B6 intakes. Am J Clin Nutr 33: 2157-2167, 1980.
23. Pocoit F, Reimers JI and Andersen HU. Nicotinamide: Biological Actions and Therapeutic Potential in Diabetes Prevention. Diabetologia 36: 574-76, 1993.
24. Pozzilli P et al. The Potential Role of Nicotinamide in the Secondary Prevention of IDDM. Diabetes Metabol Rev 9: 219-30, 1993.
25. Salem and Abdel M. The Role of Nicotinic Acid and Inositol Hexaniacinate as Anticholesterolemic and Antilipemic Agents. Nutr Rep Intl 28: 899-911, 1983.
26. Urberg M and Zemel MB. Evidence for Synergism Between Chromium and Nicotinic Acid in the Control of Glucose Tolerance in Elderly Humans. Metabolism 36: 896-99, 1987.
27. Urberg M et al. Hypocholesterolemic effect of nicotinic acid and chromium supplementation. J Fam Pract 27;6:603-6, 1988.
28. Vega GL and Crundy SM. Lipoprotein Responses to Treatment with Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients with Hypoalphalipoproteinemia, Arch Intern Med 154: 73-82, 1994.
29. Welsh AL and Ede M, Inositol Hexanicotinate for Improved Nicotinic Acid Therapy, Int Record Med 174: 9-15, 1961.

Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.